📄 medicine

Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders

This study analyzes 2023 US treatment data to reveal that opioid use disorder episodes involving co-occurring mental health disorders are characterized by distinct client demographics, higher rates of polysubstance use, and shorter treatment durations compared to those without such disorders, underscoring the need for integrated mental health and discharge support in medication treatment programs.

Original authors: Daniel L. Howard, Kechen Zhao, Alanis Goncalves Leite, Yinfei Kong

Published 2026-10-16

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Daniel L. Howard, Kechen Zhao, Alanis Goncalves Leite, Yinfei Kong

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The United States is in the midst of a severe public health emergency driven by opioid overdose, a crisis that has claimed more than 80,000 lives annually in recent years. This tragedy has evolved from a problem of prescription misuse to one dominated by illicit substances like heroin and synthetic opioids such as fentanyl. While medications that treat opioid use disorder are the most effective tool we have to save lives and reduce illegal drug use, the path to recovery is often complicated by mental health conditions. It is common for people struggling with opioid addiction to also face depression, anxiety, or other psychiatric challenges. These co-occurring issues can make treatment harder to navigate, often leaving patients caught between fragmented systems of care that do not speak to one another. Understanding how these mental health struggles intersect with opioid treatment is not just a matter of clinical detail; it is essential for designing support systems that actually work for the people who need them most.

Researchers recently turned to a massive national database to see what the treatment landscape looks like for people with and without these co-occurring mental health disorders. They examined records from 2023 for more than 109,000 treatment episodes where individuals were admitted to publicly funded programs using methadone, a standard medication for opioid use disorder. The team focused specifically on people whose records clearly stated whether they had a mental health condition, their gender, and how their treatment ended. By comparing these two groups—those with a recorded mental health disorder and those without—they could map out distinct profiles of who was seeking help, what substances they were using, and how their treatment journeys unfolded.

The data revealed that the two groups were quite different in their backgrounds and needs. People in the group with co-occurring mental health disorders were more likely to be female and White compared to the group without these disorders. Their substance use patterns were also more complex. While both groups were being treated for opioid use, the group with mental health conditions reported using alcohol, cocaine, or crack more frequently. They were also more likely to have started using their primary drug of choice at a young age, with nearly a third beginning before they turned seventeen. This group had also sought treatment before far more often, with over 85 percent having at least one prior treatment episode, compared to about 68 percent of those without mental health conditions.

The way these individuals received care also diverged significantly. Those with co-occurring disorders were much more likely to be treated in residential facilities or rehabilitation centers, where they lived at the treatment site, rather than in outpatient clinics where they visited for appointments and returned home. Despite this higher intensity of care setting, their time in treatment was actually shorter on average. The group with mental health conditions stayed for about 128 days, while the group without these conditions stayed for roughly 169 days. When they left treatment, the outcomes were also starkly different. People with co-occurring disorders were more likely to be discharged while homeless or living in dependent housing, and they were more likely to be terminated from the program by the facility rather than completing the full course of treatment.

These findings suggest that the presence of a mental health disorder marks a specific and complex profile of need that current treatment models may not fully address. The fact that this group uses more residential care but stays for a shorter time and faces higher rates of homelessness indicates that simply placing them in a facility is not enough. The researchers propose that opioid treatment programs should not view mental health status merely as a diagnostic label but as a signal for a different kind of service planning. This includes systematic screening for other substances like alcohol and stimulants, connecting patients to psychiatric care, and creating discharge plans that actively address housing instability. The study does not prove that one approach causes another, but it clearly shows that the population with co-occurring disorders faces a steeper climb, requiring a more integrated and supportive approach to ensure they can stay in treatment and recover.

Technical Summary: Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders

Problem Statement
The opioid overdose crisis in the United States remains a critical public health emergency, with annual deaths exceeding 80,000. While medications for opioid use disorder (MOUD) are the foundation of evidence-based treatment, the presence of co-occurring mental health disorders complicates clinical management. Individuals with these comorbidities often face fragmented care systems, limited integrated services, and insurance barriers. Despite the prevalence of psychiatric disorders among persons with opioid use disorder (OUD), there is a scarcity of contemporary national analyses focusing specifically on medication treatment episodes to understand how co-occurring disorders influence client demographics, substance use patterns, treatment settings, and discharge outcomes.

Methodology
This study utilized a cross-sectional analysis of the 2023 Treatment Episode Data Set-Discharges (TEDS-D), a national administrative dataset maintained by the Substance Abuse and Mental Health Services Administration (SAMHSA). The analysis focused on publicly funded treatment episodes meeting specific inclusion criteria:

Methadone use reported at admission.
Recorded status for co-occurring mental health disorders.
Recorded sex.
Discharge reasons categorized as treatment completion, dropout, or facility termination.

The final sample comprised 109,115 treatment episodes, divided into two groups: those with a recorded co-occurring mental health disorder ( $n=56,403$ ) and those without ( $n=52,712$ ). The primary grouping variable was the TEDS-D indicator for co-occurring mental health disorder.

The researchers examined demographics, admission substance use, treatment settings, US region, primary payment source, prior treatment history, length of stay, discharge reasons, recent arrests, and living arrangements. Race and ethnicity were assessed with Hispanic or Latino ethnicity prioritized over race. Continuous variables (age, length of stay) were converted from categorical TEDS-D data to approximate midpoint values. Statistical comparisons were conducted using chi-square tests for categorical variables and independent-samples t-tests for continuous variables. The analysis was descriptive and unadjusted for multiplicity or confounding.

Key Results
The analysis revealed distinct profiles between treatment episodes with and without co-occurring mental health disorders:

Demographics: Episodes with co-occurring disorders involved a significantly higher proportion of female clients (40.2% vs. 31.5%) and White clients (67.4% vs. 59.3%). The mean age at admission was slightly lower in the co-occurring group (39.7 years vs. 40.6 years). Clients in the co-occurring group also had higher rates of postsecondary education (24.9% vs. 18.5%) and unemployment at discharge (71.9% vs. 50.2%).
Substance Use: The co-occurring group exhibited higher rates of polysubstance use, including current injection drug use (37.1% vs. 29.3%), alcohol use (26.0% vs. 13.5%), cocaine or crack use (38.8% vs. 20.3%), and marijuana/hashish use (17.5% vs. 11.8%). Methamphetamine use was slightly lower in the co-occurring group (14.7% vs. 15.3%). A higher percentage of the co-occurring group reported first use of their primary substance at age 17 or younger (30.5% vs. 22.5%).
Treatment Characteristics: Episodes with co-occurring disorders were more frequently associated with rehabilitation or residential settings (30.1% vs. 11.4%) and less frequently with ambulatory care (59.2% vs. 81.2%). Furthermore, the co-occurring group had a significantly higher rate of prior treatment episodes (85.4% vs. 68.4%).
Outcomes and Discharge: Despite higher care needs, the mean length of stay was shorter for the co-occurring group (128.0 days vs. 169.3 days). While the rate of treatment completion was slightly higher in the co-occurring group (41.5% vs. 38.9%), the rate of facility termination was also higher (9.3% vs. 5.8%). Crucially, clients with co-occurring disorders were significantly more likely to be homeless or in dependent living arrangements at discharge (30.7% vs. 17.1%).

Significance and Claims
The paper concludes that co-occurring mental health disorder status marks a distinct client and service profile characterized by greater clinical complexity, including more polysubstance use, a higher reliance on residential care, and more extensive prior treatment exposure.

The authors assert that these findings support a shift in how OUD treatment programs approach service planning. Rather than viewing co-occurring status merely as a diagnostic label, it should serve as a signal for comprehensive service planning. The study advocates for:

Systematic Screening: Extending screening beyond opioid use to include mental health symptoms, alcohol use, stimulant use, and housing needs.
Integrated Care: Implementing models that coordinate medication treatment, psychiatric care, discharge planning, and housing support.
Policy Preservation: Maintaining access to public coverage and integrated treatment models for populations with complex OUD and mental health needs.

The authors acknowledge limitations, noting that TEDS-D records episodes rather than unique individuals, the co-occurring variable is a general indicator without specific diagnosis or severity data, and the data is limited to publicly funded facilities. Consequently, the findings are descriptive and should not be interpreted as causal.

Technical Summary: Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders

More like this